Kyverna Therapeutics (NASDAQ: KYTX) Sube un 9,23% debido a datos positivos de KYSA-6 y un préstamo de $150 millones

Kyverna Therapeutics (NASDAQ:KYTX) surged 9.2251% in pre-market trading on December 24, 2025, signaling renewed investor confidence ahead of year-end activity.

The rally follows a series of developments reinforcing the biotech firm’s clinical and financial momentum.

Recent updates highlighted positive interim data from its KYSA-6 Phase 2 trial for KYV-101 in generalized myasthenia gravis, with results described as setting a "new clinical standard." Analysts at HC Wainwright and Wells Fargo have upgraded price targets, with the latter raising its estimate to $27 from $24, reflecting growing optimism about the therapy’s potential across multiple indications including rheumatoid arthritis and lupus nephritis.

Strategic financing moves also bolstered sentiment. Kyverna secured a $150 million non-dilutive loan facility from Oxford Finance, addressing capital needs without equity dilution. Meanwhile, institutional activity showed mixed signals, with TD Asset Management increasing its stake while Wellington Management reduced holdings. These developments, combined with a "Moderate Buy" consensus from brokerages, suggest a pivotal phase for the stock as it navigates regulatory and market dynamics in 2026.